Drug or treatment

CAR-T clinical trials

• 525Clinical trials
• 4New in 30 days
• 34Countries

Newest trials

All recruiting trials (newest 150 of 525)

• CD19 and CD22 in vivo CAR-T therapy for relapsed/refractory B-ALL

  This study tests a one-of-a-kind in vivo CAR-T treatment that targets CD19 first and then CD22 in adults with relapsed or refractory B-ALL to see if it is safe and possibly effective.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07927816

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• Holding/bridging therapy with a bispecific antibody before CAR-T in aggressive B-cell lymphoma

  This study tests whether a short course of a CD20×CD3 bispecific antibody, given with GemOx or polatuzumab vedotin, helps patients with relapsed or refractory aggressive B-cell lymphoma proceed to planned CD19 CAR-T therapy.

  Recruiting Phase 2 National Research Center for Hematology, Russia · Moscow, Moscow · NCT07883135

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• Umbilical Cord Blood CAR-T Cells Targeting CD19 and CD22 for relapsed/refractory B-ALL

  This phase 1 study tests whether dual-target cord blood-derived CAR-T cells against CD19 and CD22 are safe and tolerable in adults with relapsed or refractory B-cell ALL.

  Recruiting Phase 1 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07838714

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• AZD0120 added to induction in multiple myeloma patients ineligible for stem cell transplant

  In people with newly diagnosed multiple myeloma who can’t have a stem cell transplant, this study tests whether a single dose of AZD0120 after standard induction therapy helps more than continuing the standard therapy.

  Recruiting Phase 3 AstraZeneca · Gilbert, Arizona and 123 other locations · NCT07764978

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

• CT0596 CAR-T in relapsed/refractory multiple myeloma: a phased dose-find and efficacy study

  This study tests CT0596 CAR-T cells in adults with relapsed/refractory multiple myeloma who have already had multiple prior treatments.

  Recruiting Phase 1/2 UCARsgen Biotech Limited · Suzhou, Jiangsu and 1 other locations · NCT07760454

• Cognitive changes after BCMA CAR-T in multiple myeloma

  This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT07740317

• AZD0120 consolidation vs ASCT in transplant-eligible newly diagnosed multiple myeloma

  This study tests whether AZD0120 given as consolidation can work as well as or better than traditional autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma.

  Recruiting at 2 sites Phase 3 AstraZeneca · Gilbert, Arizona and 113 other locations · NCT07735637

• Low-Dose TBI Plus CAR-T Therapy for relapsed/refractory DLBCL or multiple myeloma

  This trial tests whether giving a single low dose of total body irradiation before CAR-T therapy is safe and helps the treatment work better for adults with relapsed or refractory DLBCL or multiple myeloma.

  Recruiting Phase 1 Weill Medical College of Cornell University · New York, New York · NCT07725406

• In Vivo PICX CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

  A single-arm study is testing an in vivo CAR-T cell therapy (PICX Injection) to see if it is safe and can help people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07715630

• BCMA-CD19 cCAR-T cell therapy for refractory inflammatory myopathy

  This trial tests a special CAR-T cell therapy (ICG318) in adults with refractory inflammatory myopathy to see if it is safe and tolerable.

  Recruiting Phase 1 iCell Gene Therapeutics · Chengdu, Sichuan · NCT07715136

• CAR-T Cell Therapy for B-ALL (relapsed/refractory)

  This trial tests a patient’s own CAR-T cells to treat relapsed or refractory B-cell ALL in people aged 5–50.

  Recruiting Early Phase 1 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi · NCT07695012

• CAR-T therapy for relapsed or refractory multiple myeloma

  This study tests a CAR-T therapy in people with multiple myeloma whose disease has come back or not responded to treatment.

  Recruiting at 2 sites Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi, Punjab Province and 1 other locations · NCT07689058

• AZD4045 in Relapsed or Refractory Multiple Myeloma

  This study tests AZD4045 alone and with daratumumab and aldesleukin in adults whose multiple myeloma has returned or stopped responding to treatment.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 11 other locations · NCT07681596

• CD19 CAR-T therapy for refractory pemphigus vulgaris

  This study tests autologous CD19 CAR-T cells in adults with moderate-to-severe, treatment-refractory pemphigus vulgaris to see if it is safe and may reduce disease activity.

  Recruiting Wuhan Integrated Traditional Chinese and Western Medicine Hospital · Wuhan, Hubei · NCT07681388

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• Nemtabrutinib Plus Brexucabtagene Autoleucel (Brexu-Cel) in Relapsed or Refractory Mantle Cell Lymphoma

  This phase 2 trial tests whether adding nemtabrutinib to brexu-cel can help people whose mantle cell lymphoma has come back or not responded to prior treatment.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07673367

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Understanding CAR-T Toxicities After Cilta-Cel in Multiple Myeloma

  This observational study tests how patients with multiple myeloma respond to cilta-cel treatment by tracking toxicities and trying to spot biomarkers to guide care.

  Recruiting at 3 sites Icahn School of Medicine at Mount Sinai · San Francisco, California and 2 other locations · NCT07665307

• Allogeneic CD70 CAR-T Therapy for Unresectable or Metastatic Clear Cell RCC

  This trial tests ET-970, a donor-derived CD70 CAR-T cell therapy, to see if it is safe and shows signs of effectiveness in people with unresectable or metastatic clear cell renal cell carcinoma.

  Recruiting at 3 sites Early Phase 1 Chinese PLA General Hospital · Beijing and 2 other locations · NCT07645690

• In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases

  This open-label, single-arm study tests Arnovie101, an mRNA-LNP-based in vivo CAR-T therapy, in adults with relapsed or refractory SLE or AIHA to see if it is safe and how the body handles it.

  Recruiting Early Phase 1 Circunited BioPharma (Shenzhen) Co., Ltd. · Beijing, Beijing Municipality · NCT07629596

• Allogeneic CAR-T CT0890B for relapsed/refractory AML

  This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.

  Recruiting Phase 1 Peking University People's Hospital · Beijing · NCT07617285

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• Autologous p95HER2 CAR-T Cells in HER2-Positive Cancers

  This study tests whether a patient’s own CAR-T cells targeting p95HER2 can be safely given to adults with HER2-positive metastatic cancers to see if it can help control tumors.

  Recruiting Phase 1 Vall d'Hebron Institute of Oncology · Barcelona, Catalonia and 1 other locations · NCT07593820

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• CD19/CD22 CAR-T as first-line consolidation for follicular lymphoma

  This trial tests whether CAR-T cells targeting CD19 and CD22 can be used as a first-line consolidation therapy for people with follicular lymphoma to see if it improves outcomes.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07587840

• In Vivo BCMA/GPRC5D Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

  A first-in-human, single-center study tests a two-target CAR-T cell therapy given in vivo to see if it is safe and tolerable in adults with relapsed or refractory plasma cell neoplasms.

  Recruiting Early Phase 1 Chinese PLA General Hospital · Beijing · NCT07586709

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• Dual-target CD22/CD19 CAR-T consolidation after first remission in high-risk B-ALL

  This test will try a dual-target CD22/CD19 CAR-T cell treatment as consolidation for patients with high-risk B-cell acute lymphoblastic leukemia who are in their first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575971

• CD22/CD19 CAR-T consolidation for adults with standard-risk B-ALL

  This study will try dual-target CD22/CD19 CAR-T cell therapy as a consolidation treatment for adults with standard-risk B-cell acute lymphoblastic leukemia who are in first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575919

• IL-8 receptor–modified CAR T cells for brain metastases in adults

  This phase 1 study tests whether patient-derived, IL-8 receptor–modified CD70 CAR T cells can be safely given to adults with brain metastases.

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT07569263

• DJI136 CAR-T therapy for extensive-stage small cell lung cancer

  Researchers are testing DJI136, a CAR-T cell therapy, to see if it can help adults with extensive-stage small cell lung cancer who have already tried standard treatments.

  Recruiting at 7 sites Phase 1/2 Novartis · Lexington, Kentucky and 6 other locations · NCT07564401

• LNK001 CAR T therapy in advanced clear cell kidney cancer

  This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07564232

• Locally delivered EGFR/IL13Rα2 CAR T-cell therapy for recurrent high-grade gliomas

  This phase I study tests whether a patient's own EGFR/IL13Rα2 CAR T cells, given directly into the brain, are safe and can help adults with recurrent or progressive high-grade gliomas.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07544992

• CAR-T plus autologous stem-cell transplant for relapsed or high-risk large B‑cell lymphoma

  This trial will try CAR-T cell therapy together with an autologous stem-cell transplant in adults whose large B‑cell lymphoma has relapsed or is refractory and who have high‑risk features.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhengjiang · NCT07538635

• Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma

  This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.

  Recruiting Phase 1 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07532525

• Universal (allogeneic) CAR T-cell therapy targeting CD19 and BCMA for relapsed/refractory autoimmune hemolytic anemia

  This trial will try a single infusion of universal anti‑CD19/BCMA CAR T-cells for people aged 10 and up whose autoimmune hemolytic anemia has not responded to at least three prior treatments.

  Recruiting Early Phase 1 The Second Hospital of Anhui Medical University · Hefei · NCT07530380

• Allogeneic anti-CD7 CAR-T therapy for type 1 diabetes

  This trial will test an off-the-shelf anti-CD7 CAR-T cell therapy in adults 18–40 with stage 2 or 3 type 1 diabetes to see if it can safely reduce the immune attack on insulin-producing beta cells.

  Recruiting Early Phase 1 Shanghai Zhongshan Hospital · Shanghai · NCT07528105

• Academic anti-CD19 CAR-T for relapsed or refractory large B‑cell lymphoma

  This project tests whether a locally manufactured anti‑CD19 CAR‑T cell therapy works and is safe for adults whose large B‑cell lymphoma has relapsed or not responded to prior treatment.

  Recruiting N.N. Alexandrov National Cancer Centre · Lyasny, Minsk Oblast · NCT07524816

• Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers

  This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523555

• Biomarker-guided CAR-T target selection for refractory lupus

  This trial tests whether using a lab-based immune profile to pick CD19- or BCMA-targeted CAR-T can help adults with refractory lupus, including lupus nephritis, who have not responded to standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523542

• Personalized dual-target CAR-T therapy for advanced solid tumors

  This trial will test personalized dual-target CAR-T cells, matched to tumor biomarker patterns, in adults with advanced unresectable or metastatic solid cancers to see if dual targeting improves tumor control and safety.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523529

• CAR70-BCMA CAR-T Cells for Relapsed or Refractory Plasma Cell Neoplasms

  A one-arm study tests a dual-target CAR-T therapy (CAR70-BCMA) in people whose plasma cell cancers have come back or not responded to prior treatment to see if it is safe and could help.

  Recruiting Early Phase 1 The General Hospital of Western Theater Command · Chengdu, Chengdu · NCT07519187

• IL-15–armored CAR-T for relapsed or refractory multiple myeloma and plasma cell leukemia

  This trial will test IL-15–armored CAR-T cell therapy to see if it helps adults with relapsed or refractory multiple myeloma or plasma cell leukemia, including those with persistent or returning MRD.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07509086

• Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease

  This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07507201

• Anti-CD19 CAR T-cell therapy for severe systemic sclerosis that didn’t respond to standard treatment

  This study tests whether a patient’s own anti-CD19 CAR T-cells can help reduce skin thickening and other disease activity in adults with active, treatment-resistant systemic sclerosis.

  Recruiting Phase 2 University Hospital, Montpellier · Lille and 3 other locations · NCT07493395

• Super CAR-T therapy for GPC3-positive advanced liver cancer

  This trial tests a single infusion of Super CAR-T cell therapy in adults with advanced, GPC3-positive hepatocellular carcinoma who have failed at least two standard treatments.

  Recruiting Phase 1 Guangzhou FineImmune Biotechnology Co., LTD. · Guangzhou, Gaungdong · NCT07493044

• CD19/BCMA CAR-T therapy for refractory autoimmune diseases

  This study tests a CD19/BCMA CAR-T treatment in adults with difficult-to-treat autoimmune diseases to see if it is safe and may help control their disease.

  Recruiting at 2 sites Wuhan Integrated Traditional Chinese and Western Medicine Hospital · Wuhan, Hubei and 2 other locations · NCT07490951

• Combining CAR‑T therapy with chidamide and a PD‑1 blocker for B‑cell lymphoma

  This Phase 2 trial will try adding chidamide and a PD‑1 inhibitor as maintenance after CAR‑T therapy for people with relapsed or high‑risk diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07489989

• PD-1Ab21-BCMA CAR-T consolidation for multiple myeloma with renal dysfunction

  This trial will test a BCMA-targeted CAR-T cell therapy that secretes a PD-1 antibody and interleukin-21 fusion protein as consolidation treatment for people with multiple myeloma who have kidney dysfunction.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07489534

• First-in-human ML261 CAR T therapy for relapsed/refractory SCLC and select neuroendocrine cancers

  This early-phase study tests whether a patient’s own ML261 CAR T cells can be safely given to see if they help people with relapsed or refractory SCLC or certain neuroendocrine cancers.

  Recruiting at 7 sites Phase 1 Moonlight Bio, Inc · St Louis, Missouri and 6 other locations · NCT07488923

• At-home cognitive training and mindfulness for children after CAR-T, transplant, or chemotherapy

  This program tests whether remote digital cognitive exercises combined with adapted mindfulness can help thinking, behavior, and brain function in children and teens treated for acute lymphoblastic leukemia after CAR‑T, chemotherapy, or transplant.

  Recruiting Hospital Universitario La Paz · Madrid, Madrid · NCT07479927

• Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

  This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07478848

• Anti-BCMA CAR‑T therapy for adults with relapsed or refractory multiple myeloma

  This tests whether a patient's own engineered anti-BCMA CAR‑T cells can help adults whose multiple myeloma has come back or stopped responding to treatment and whether the approach is safe.

  Recruiting Phase 1/2 Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology · Minsk · NCT07477912

• Targeted activated dendritic cell plus CAR‑T therapy for advanced solid cancers

  This trial will try combining activated dendritic cells with CAR‑T cells to see if the treatment is safe and helps adults with advanced solid tumors that express Claudin 18.2, GCC, TROP2, or PSMA.

  Recruiting Early Phase 1 Hainan Cancer Hospital · Haikou, Hainan · NCT07475182

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• Dynamic individualized risk profiling for patients receiving CD19 CAR T-cell therapy

  This project tries a combined blood, imaging, and lab test to predict which adults with relapsed or refractory B‑cell lymphoma will do well after CD19 CAR T‑cell therapy.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07472972

• Universal CAR‑T (CT1190B) for CD19 and/or CD20 positive relapsed/refractory B‑cell acute lymphoblastic leukemia in patients aged 12–75

  This trial will test whether an off‑the‑shelf CAR‑T product (CT1190B) is safe and can induce remission in CD19 and/or CD20 positive relapsed or refractory B‑cell acute lymphoblastic leukemia for patients aged 12–75.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07470073

• CART123 Cells With or Without Ruxolitinib for Relapsed/Refractory AML

  This trial tests CART123 cells alone or with ruxolitinib to see if they help kids and young adults with relapsed or treatment‑resistant AML.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07464951

• Glofitamab for mantle cell lymphoma after CAR-T failure

  This phase 2, multicenter, single-arm study tests glofitamab in adults with mantle cell lymphoma who did not respond to or relapsed after CAR-T cell therapy.

  Recruiting Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria and 13 other locations · NCT07453095

• Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers

  This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07451054

• Dual-target universal CAR-T cell therapy for refractory lupus

  This trial will test an off-the-shelf dual-target CAR-T cell therapy (QT-019B) to see if it is safe and tolerable in adults with refractory systemic lupus erythematosus.

  Recruiting at 3 sites Phase 1 Hangzhou Qihan Biotech Co., Ltd. · Hefei, Anhui and 2 other locations · NCT07444307

• CAR-T therapy to try for active residual disease in LBCL

  This phase 1b study tests whether YTB323 CAR-T cells can help adults with large B-cell lymphoma who still have measurable residual disease after initial therapy.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07443137

• UCAR-T cells targeting CD19 and BCMA for autoimmune blood disorders

  This treatment tests an off-the-shelf UCAR-T cell therapy that targets CD19 and BCMA to try to treat adults with antibody-driven blood disorders like ITP, autoimmune hemolytic anemia, and Evans syndrome.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07441525

• CD19 CAR-T versus donor lymphocyte infusion for clearing MRD after allogeneic stem cell transplant in Ph-negative B-ALL

  This trial tests whether a single infusion of autologous CD19 CAR-T cells or chemotherapy plus donor lymphocyte infusion better clears minimal residual disease in patients aged 3–79 with Ph-negative B‑cell ALL after allogeneic stem cell transplant.

  Recruiting Phase 3 Peking University People's Hospital · Beijing, China · NCT07441291

• Autologous CAR-T cell treatment for refractory and relapsing ulcerative colitis

  This study will try autologous CAR‑T cell injections to see if they can bring 12‑week clinical remission in people with moderate‑to‑severe ulcerative colitis who have not responded to approved treatments.

  Recruiting Early Phase 1 Hebei Senlang Biotechnology Inc., Ltd. · Guangzhou · NCT07435779

• End-of-chemotherapy B7-H3 CAR T cells for high-risk pediatric osteosarcoma

  This study tests whether giving a patient’s own B7-H3 CAR T cells after standard chemotherapy can help treat newly diagnosed high-risk osteosarcoma in children.

  Recruiting Phase 2 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07428993

• CAR BCMA-CD70 CAR-T Cells for High-risk Plasma Cell Neoplasms

  This early-phase, single-arm study tests a CAR-T cell therapy called CAR BCMA-CD70 for adults with high-risk plasma cell cancers to see if it is safe and can help control the disease.

  Recruiting Early Phase 1 Affiliated Hospital to Academy of Military Medical Sciences · Beijing, Beijing Municipality · NCT07416682

• Claudin18.2-targeted activated dendritic cell plus CAR-T therapy for advanced pancreatic cancer

  This trial will test whether combining Claudin18.2-targeted activated dendritic cells with Claudin18.2 CAR-T cells helps people with advanced pancreatic cancer whose tumors express Claudin18.2.

  Recruiting Early Phase 1 Hainan Cancer Hospital · Haikou, Hainan · NCT07416240

• Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients

  This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07403812

• CD19 CAR-T (PTOC1) therapy for refractory systemic lupus erythematosus

  This study will try a fast-made CD19 CAR-T cell treatment called PTOC1 in people aged 5 and older whose lupus has not improved with high-dose steroids and multiple immunosuppressive drugs.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Chongqing · NCT07403097

• MSLN CAR-T for advanced malignant tumors

  This trial will test whether a single infusion of MSLN-targeted CAR-T cells is safe and can shrink tumors in adults (18–75) with stage III/IV solid cancers that express mesothelin.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07399769

• Oncolytic vaccinia virus delivering CD19 to create CAR‑T therapy inside the body for relapsed/refractory B‑cell lymphoma

  This treatment uses an oncolytic vaccinia virus that delivers a CD19 CAR inside the body to try to treat adults with relapsed or refractory B‑cell lymphoma.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07398963

• In vivo CAR‑T treatment targeting BCMA, GPRC5D, DLL3, and FcRH5 for advanced tumors

  This trial will try an in-body CAR-T injection to treat adults with relapsed or refractory advanced blood cancers or solid tumors that express BCMA, GPRC5D, DLL3, or FcRH5.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07395479

• AZD0120 dual-target CAR-T (BCMA and CD19) versus standard treatments for relapsed refractory multiple myeloma

  This trial tests whether a dual-target CAR-T therapy called AZD0120 works better than commonly used drug regimens for adults with relapsed or refractory multiple myeloma.

  Recruiting at 40 sites Phase 3 AstraZeneca · Gilbert, Arizona and 142 other locations · NCT07391657

• Remote rehabilitation for people receiving CAR-T cell therapy

  This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07390071

• JV-394 CAR T therapy for relapsed or refractory CD94-positive T/NK-cell cancers

  This trial will test whether using a patient’s own modified immune cells (JV-394 CAR T) is safe and find the best dose for adults with relapsed or refractory CD94-positive T/NK-cell lymphoma.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07382817

• DC/MM fusion vaccine plus BCMA CAR-T for relapsed or refractory multiple myeloma

  This trial will test whether adding a personalized DC/MM fusion vaccine (with GM‑CSF) to standard BCMA CAR‑T therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07377435

• BAFF‑R CAR‑T treatment for adults with CD19‑negative relapsed or refractory B‑cell lymphoma

  This trial will see if BAFF‑R CAR‑T cells are safe and tolerable for adults whose B‑cell lymphoma has returned or not responded and is CD19‑negative.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07369492

• Anti‑PD1 armored CD19 CAR‑T therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test whether anti‑PD1 armored CD19 CAR‑T cell therapy is safe and tolerable in adults with relapsed or refractory diffuse large B‑cell lymphoma.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07368270

• Adding CLS-015 to anti-CD19 CAR-T therapy for large B‑cell lymphoma during lymphodepletion

  This trial tests whether giving CLS-015 (an enzyme that breaks down NETs) alongside anti‑CD19 CAR‑T therapy helps adults with large B‑cell lymphoma who have stable or progressing disease at the time of lymphodepletion.

  Recruiting Phase 1 Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07361224

• Dual-target CD19/BCMA CAR-T therapy for relapsed or refractory multiple myeloma

  This study will try a CAR-T treatment that targets both CD19 and BCMA to see if it helps people whose multiple myeloma has returned or not responded to prior therapies.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07359014

• CT1195E CAR-T cell therapy for refractory or progressive systemic sclerosis

  This trial will test whether CT1195E CAR-T cell therapy is safe and helps adults (18–60) with refractory or progressive systemic sclerosis.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07355972

• CAR-T therapy targeting CD19 and BCMA to desensitize highly sensitized kidney transplant candidates

  This will test whether AZD0120, a dual CD19/BCMA CAR-T cell therapy, can safely reduce donor-specific antibodies and enable kidney transplant in highly sensitized adults with end-stage kidney disease.

  Recruiting Early Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07350837

• CD64 CAR T Therapy for Adults with Relapsed or Refractory AML

  This phase 1 study tests a patient’s own CD64-directed CAR T cells to see if they can be safely given and potentially help adults with relapsed or refractory AML.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT07347418

• BAFFR CAR-T therapy for relapsed or treatment-resistant B‑cell cancers

  This study will try BAFFR-directed CAR-T cell therapy in adults whose B‑cell cancers have come back or not responded to prior treatments to see if it is safe and works.

  Recruiting Tongji Hospital · Wuhan · NCT07345728

• Dual CD19 and CD20 CAR-T therapy for relapsed or refractory aggressive B-cell lymphoma

  This trial will try a CAR-T treatment that targets both CD19 and CD20 for adults whose aggressive B-cell lymphoma has relapsed or not responded to prior therapies.

  Recruiting Early Phase 1 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07344818

• Monitoring CAR‑BCMA immune cells in multiple myeloma

  This project will test whether tracking CAR‑BCMA cells and related immune markers in blood and bone marrow can help predict which multiple myeloma patients respond to CAR‑T therapy.

  Recruiting Poitiers University Hospital · Poitiers · NCT07342179

• Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

  This trial tests whether adding two oral drugs, sonrotoclax and zanubrutinib, to standard CAR-T therapy helps people with mantle cell lymphoma who have relapsed or are refractory after prior treatment.

  Recruiting at 5 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 4 other locations · NCT07341191

• Universal CD19/CD20 CAR-T cell injection for moderate to severe refractory systemic lupus erythematosus

  This study will try a universal CD19/CD20 CAR‑T cell infusion (CT1195E) to see if it is safe and helps adults 18–65 with moderate to severe refractory SLE.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07339332

• CD19/BCMA-targeted UCAR-T for neurological autoimmune disorders

  This trial tests an off-the-shelf CD19/BCMA UCAR-T cell therapy with lymphodepletion in adults with relapsing or treatment-resistant MS, myasthenia gravis, CIDP, or autoimmune encephalitis.

  Recruiting Early Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07337785

• In vivo CAR-T treatment for refractory Graves' disease

  This trial will test HN2301, an in‑body CAR‑T therapy, to see if it can control thyroid autoimmunity in adults whose Graves' disease has not responded to standard antithyroid drugs.

  Recruiting Early Phase 1 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07333677

• Ultra-fast autologous CD19 CAR-T therapy for refractory SLE

  This trial will try ultra-fast autologous CD19 CAR-T cells to see if they can control disease in adults with refractory systemic lupus erythematosus.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07331467

• A CAR-T therapy for hard-to-treat systemic lupus with or without lupus nephritis

  This phase 2a study tests a single infusion of ICG318 CAR-T cells in adults and eligible teens with refractory SLE, with or without lupus nephritis.

  Recruiting Phase 2 iCell Gene Therapeutics · Chicago, Illinois and 3 other locations · NCT07328581

• Using CD22 CAR T-cells to extend remission after commercial CD19 CAR T-cell therapy in children, adolescents, and adults with relapsed/refractory B‑ALL

  This will try giving CD22-targeted CAR T-cells to people aged 3–65 who are in remission after CD19 CAR T-cell therapy to see if it helps keep their B-ALL from coming back longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07328503

• Nanoparticle-delivered CAR1920 mRNA CAR‑T targeting CD19 and CD20 for relapsed or refractory B‑cell lymphoma/leukemia

  This trial tests whether polymer-lipid nanoparticles can deliver CAR1920 mRNA to program a patient's T cells to target CD19 and CD20 in people with relapsed or refractory B‑cell lymphoma or leukemia.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07321301

• Ultra-fast BCMA/CD70 CAR-T therapy for refractory lupus

  This trial will test ultra-fast BCMA/CD70 CAR-T cell therapy in adults with systemic lupus erythematosus that has not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Nanjing, Jiangsu · NCT07318259

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases

  This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07315087

• Geriatric assessment before CAR‑T or bispecific antibody therapy to predict side effects and outcomes in older adults

  This study will test whether a brief geriatric assessment done before CAR‑T or bispecific antibody treatment can help predict side effects and outcomes for people aged 65 and older with aggressive lymphoma or multiple myeloma.

  Recruiting at 2 sites University of Zurich · Bern and 1 other locations · NCT07309497

• GP350 CAR-T for relapsed or EBV-associated lymphoid neoplasms

  This trial will try GP350 CAR-T cell therapy in people with relapsed or refractory lymphoid cancers that are linked to Epstein-Barr virus.

  Recruiting Phase 1/2 The Second Hospital of Anhui Medical University · Hefei, Anhui · NCT07306156

• Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases

  This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07305116

• Anti-CCR9 CAR T-cell therapy for T‑cell acute lymphoblastic leukaemia and lymphoblastic lymphoma

  We will try anti-CCR9 CAR T cells made from your own blood to find a dose that is safe for children and adults with relapsed or refractory T‑cell leukaemia or lymphoma.

  Recruiting Phase 1 University College, London · London · NCT07300683

• Off-the-shelf CAR-T Allo-QuadCAR01-T targeting CD19 and CD20 for relapsed or refractory B‑cell cancers

  This study will test an off-the-shelf donor CAR-T that targets CD19 and CD20 to try to treat adults with relapsed or refractory B‑cell lymphomas or leukemias.

  Recruiting at 6 sites Phase 1/2 AvenCell Therapeutics, Inc. · Chicago, Illinois and 12 other locations · NCT07284433

• Umbilical cord blood CAR-T therapy for refractory systemic lupus erythematosus

  This will test an off-the-shelf umbilical cord blood–derived CAR‑T cell therapy targeting CD19 and BCMA to see if it helps adults with treatment‑resistant SLE.

  Recruiting Early Phase 1 Chengdu Ucello Biotechnology Co., Ltd. · Yancheng, Jiangsu and 1 other locations · NCT07274059

• CD19 CAR-T therapy for refractory primary membranous nephropathy

  This will try CD19 CAR-T cell therapy in people with primary membranous nephropathy that has not responded to standard immunosuppressive treatments.

  Recruiting Phase 1 The First Affiliated Hospital of Air Force Medical University · Xi'an, China · NCT07266181

• LILRA6 CAR-T therapy for relapsed or refractory acute myeloid leukemia.

  This trial will test LILRA6-directed CAR-T cell therapy to see if it helps adults (18–75) whose acute myeloid leukemia has returned or not responded to prior treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07263906

• Allogeneic dual CD19/BCMA CAR-T therapy for refractory Graves' disease

  This will test an off-the-shelf CAR-T treatment that targets CD19 and BCMA to see if it can produce lasting remission in people whose Graves' disease has not responded to standard medications.

  Recruiting Early Phase 1 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07261345

• IL-5 CAR-T therapy for refractory or relapsed eosinophilic leukemia

  We will test whether IL-5 CAR-T cells can help adults with CD125-positive refractory or relapsed eosinophilic leukemia.

  Recruiting Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT07257640

• CD19‑CAR T‑cell consolidation after TCRαβ/CD19‑depleted haploidentical family donor transplant for relapsed/refractory CD19+ B‑cell leukemia and lymphoma

  This will try giving CD19‑targeted CAR T cells shortly after a partially matched family‑donor transplant to children and young adults (≤21) with relapsed or refractory CD19+ B‑cell leukemia or lymphoma to see if the approach is safe and feasible.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07257419

• CD19 CAR-T for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia

  This study will test CD19 CAR‑T cell therapy in adults newly diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia to see if it can induce remission.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07252336

• CEA-targeted CAR-T therapy for advanced CEA-positive solid tumors

  This trial will try a CEA-targeted CAR-T cell therapy in adults with advanced, CEA-positive non-small cell lung cancer or breast cancer who have progressed after standard treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07250386

• Asciminib maintenance after alloHCT or CAR T for adults with Ph+ ALL

  Doctors will try asciminib in adults with Ph+ ALL who are in remission after an allogeneic stem cell transplant or CAR T therapy to check safety and find the best dose to help prevent relapse.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07250087

• Voice monitoring for side effects during CAR T-cell therapy

  This project will test whether twice-daily smartphone voice recordings and brief daily neurologic checks can spot early neurologic side effects in adults receiving FDA-approved CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07249528

• Dual-target CAR-T therapy (CAR19-BCMA) for relapsed or refractory multiple myeloma

  This trial will test whether a dual-target CAR-T cell therapy that targets CD19 and BCMA is safe and tolerable for adults with relapsed or refractory multiple myeloma.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07249073

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

• Universal CAR-T therapy for CD19-positive B‑cell non-Hodgkin lymphoma

  This study will try an off‑the‑shelf CAR‑T product called BRL‑301 in adults with CD19‑positive B‑cell non‑Hodgkin lymphoma to see if a single 5×10^6/kg dose is safe and shows anti‑tumor activity.

  Recruiting Bioray Laboratories · Shanghai · NCT07248163

• CEA-targeted CAR-T therapy after cytoreductive surgery for peritoneal colorectal cancer

  This trial will test whether CEA-targeted CAR-T cells delivered into the abdomen after cytoreductive surgery can help people with colorectal cancer that has spread to the peritoneum.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07247396

• Senl_B19 (S1904) CD19 CAR-T for relapsed or refractory CD19+ B-ALL in children and young adults

  This trial will test S1904 (Senl_B19) CD19 CAR-T cells in children and young adults aged 3–25 with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.

  Recruiting Phase 2 Hebei Senlang Biotechnology Inc., Ltd. · Beijing · NCT07244406

• Anti-CD19/BCMA CAR-T (KN3601) for relapsed or refractory immune-mediated kidney disease

  This pilot will try an anti-CD19/BCMA CAR-T cell infusion (KN3601) to see if it is safe and helps adults with relapsed or refractory immune-mediated kidney disease.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT07241468

• In vivo CAR-T therapy for relapsed or refractory B‑cell leukemias, lymphomas, and multiple myeloma

  This trial will try a single in‑body (intravenous) CAR‑T infusion to treat adults with relapsed or refractory B‑cell acute lymphoblastic leukemia, B‑cell non‑Hodgkin lymphoma, or multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07239323

• Predictors of response to CD19 CAR-T therapy in relapsed/refractory large B‑cell lymphoma

  This study will see if clinical features, tumor biology, and immune cell changes can predict who responds to CD19 CAR‑T therapy for relapsed/refractory large B‑cell lymphoma.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07236203

• Ultra-fast autologous CD19 CAR-T therapy for refractory systemic lupus erythematosus

  This trial will try ultra-fast autologous CD19 CAR-T cell therapy in people aged 5 and older with moderate-to-severe SLE that has not responded to high-dose steroids and multiple immunosuppressants.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07233642

• FH-FOLR1 CAR T cell therapy for advanced or recurrent osteosarcoma

  This trial will test whether FH-FOLR1 CAR T cells are safe and what dose works best in people aged 1–75 with advanced, recurrent, or treatment-resistant osteosarcoma.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07227571

• Fludarabine dosing for children and young adults with B-cell acute lymphoblastic leukemia

  This trial will test whether pharmacokinetic (PK)-targeted fludarabine dosing before tisagenlecleucel CAR T-cell therapy helps children and young adults with relapsed or refractory B‑cell ALL more than standard fludarabine dosing.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · New York, New York and 7 other locations · NCT07223021

• Hypofractionated radiation plus B7-H3 CAR T cells for children and young adults with relapsed sarcoma

  This will test whether short-course radiation given before B7-H3 CAR T-cell therapy is safe for children and young adults (≤21) with relapsed or refractory B7-H3–positive sarcomas.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222735

• FT836 CAR T-cell Therapy with Daratumumab in relapsed/refractory multiple myeloma

  This phase 1 study tests whether FT836 CAR T cells given with daratumumab are safe and show early signs of activity in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07221032

• CD7 CAR T therapy for high-risk T-cell cancers

  This study tests a patient’s own edited T cells, engineered to target CD7, in people with relapsed or high-risk T-cell leukemia or lymphoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT07220993

• Umbilical cord mesenchymal stem cell treatment for persistent cytopenia after CAR‑T

  This trial will try giving umbilical cord blood–derived mesenchymal stem cells to adults with persistent severe low blood counts three weeks after CAR‑T therapy to see if their blood counts recover and to check safety.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07212335

• NKG2D.zeta-NK cells plus C7R.GD2.CAR-T cells for relapsed or refractory neuroblastoma or osteosarcoma

  This study tests a combination of modified NK cells and CAR-T cells to see if it can safely help patients with GD2-expressing relapsed or refractory neuroblastoma or osteosarcoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT07211737

• Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases

  This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07203404

• Selinexor maintenance after CAR-T for multiple myeloma

  This Phase 1 test will see if taking selinexor after ciltacabtagene autoleucel (cilta‑cel) helps adults with relapsed, triple-class exposed or refractory multiple myeloma stay in remission longer.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07200102

• NT-I7 added to BCMA CAR-T therapy for relapsed or refractory multiple myeloma

  This trial tests whether giving NT-I7 after BCMA CAR-T therapy helps boost T-cell expansion and possibly improve responses in people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07200089

• CD19 CAR-T therapy for relapsed or refractory autoimmune diseases

  This trial will try CD19 CAR-T cell therapy in adults with relapsed or refractory autoimmune diseases to see if it controls disease activity and allows stopping immunosuppressive drugs.

  Recruiting ShenZhen Cell Valley · Shenyang, Liaoning · NCT07193667

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Digital health program for self-management and remote monitoring during outpatient CAR-T therapy

  This Phase 3 study tests whether a remote patient-monitoring and education program helps adults with relapsed or refractory blood cancers and their family caregivers manage symptoms during and after outpatient CAR-T therapy.

  Recruiting Phase 3 City of Hope Medical Center · Duarte, California · NCT07186192

• BCMA/CD70-directed CAR-T for children with hard-to-treat rheumatic diseases

  This trial will try a BCMA/CD70-directed CAR-T therapy in children aged 5 and older whose rheumatic diseases have not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT07184450

• CEA-targeted CAR-T for advanced CEA-positive solid tumors

  This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui · NCT07179692

• CT041 after first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction cancer

  This study will test CT041, an autologous CLDN18.2-targeted CAR T-cell treatment, for people with advanced gastric or gastroesophageal junction adenocarcinoma after completing first-line therapy.

  Recruiting Beijing GoBroad Hospital · Beijing · NCT07179484

• CD19/CD22/BCMA CAR‑T (BZE2204) for relapsed or refractory autoimmune diseases

  This will test whether a personalized CAR‑T cell therapy (BZE2204) targeting CD19, CD22, and BCMA can help adults with relapsed or refractory IIM, ITP, or SLE.

  Recruiting Early Phase 1 Shanghai Cell Therapy Group Co.,Ltd · Shanghai, Shanghai Municipality · NCT07174843

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of CAR-T are recruiting right now?

525, as of November 12, 2026. 4 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 34 countries. The most sites are in China (289 trials), United States (170 trials), Italy (17 trials), France (17 trials), United Kingdom (15 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 194, Phase 1/2: 83, Early Phase 1: 77, Phase 2: 77. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →